W H Irelandreprice AMTE UHP Line23 Aug 2022 10:45
"UHP upside Addressing the valuation of the UHP cells alone, based on our interpretation of this morning’s update, reveals the value opportunity inherent in just this one product. Our indicative valuation is based on assumptions around the total addressable market for this product (interestingly, our cell production estimates, based on addressable TAM, align to the name plate capacity of the proposed facility in Dundee), discounted back over the next ten years on a conservatively framed 13% WACC (versus the 11.5% we previously applied, recognising the increased risk with respect to capital funding). Our revised calculations (based on higher selling pricings, likely better gross margins (vs our conservative estimates at the time of IPO) suggest a value for this one revenue stream of some ca.£220m (assuming UHP buildout cost of ca.£260m, in two phases to allow two production lines – AMTE has announced its plans for the first production line), significantly ahead of the £60m value we attributed to it in our initiation research on AMTE. This is, in turn, well ahead of the company’s market cap, following the tech sell-off, of £33m. "